{
    "2020-11-09": [
        [
            {
                "time": "2020-11-09",
                "original_text": "Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19",
                "features": {
                    "keywords": [
                        "bamlanivimab",
                        "FDA",
                        "emergency use authorization",
                        "COVID-19"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "n/a"
                }
            },
            {
                "time": "2020-11-09",
                "original_text": "Price Over Earnings Overview: Eli Lilly",
                "features": {
                    "keywords": [
                        "Price Over Earnings",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "n/a",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}